Enfanos

Executive Summary

Enfanos is a San Francisco-based biotechnology company founded in 2018 by University of Washington scientists, specializing in custom multiplex research methods and reagents for enzyme activity assays using mass spectrometry. The company focuses on making advanced lysosomal enzyme assays accessible to the global research community, particularly for newborn screening and pediatrics. Its core offerings include assay kits and reagents that enable precise measurement of enzyme activity, addressing a critical need in early disease detection. While still private with limited disclosed funding and valuation, Enfanos occupies a niche but important position in the digital health and pediatrics sectors, leveraging mass spectrometry-based analysis to improve the accuracy and efficiency of newborn screening programs. The company's technology has the potential to expand the panel of detectable lysosomal storage disorders, thereby enhancing early intervention and patient outcomes.

Upcoming Catalysts (preview)

• Q4 2026Partnership or collaboration with a major newborn screening program or hospital network40% success
• H1 2027Launch of expanded assay panel covering additional lysosomal storage disorders50% success
• Q3 2026Receipt of government or foundation grant for technology development or clinical validation60% success